REIT - Healthcare Facilities
Compare Stocks
4 / 10Stock Comparison
SILA vs CHCT vs GMRE vs MDRR
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Healthcare Facilities
REIT - Diversified
SILA vs CHCT vs GMRE vs MDRR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Diversified |
| Market Cap | $1.69B | $505M | $94M | $12M |
| Revenue (TTM) | $198M | $122M | $148M | $10M |
| Net Income (TTM) | $33M | $6M | $2M | $-2M |
| Gross Margin | 87.9% | 62.8% | 68.8% | — |
| Operating Margin | 34.5% | 31.3% | 24.9% | 5.3% |
| Forward P/E | 47.0x | 37.6x | 595.7x | — |
| Total Debt | $721M | $536M | $654M | $785K |
| Cash & Equiv. | $32M | $3M | $7M | $3M |
SILA vs CHCT vs GMRE vs MDRR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 24 | May 26 | Return |
|---|---|---|---|
| Sila Realty Trust, … (SILA) | 100 | 144.4 | +44.4% |
| Community Healthcar… (CHCT) | 100 | 75.6 | -24.4% |
| Global Medical REIT… (GMRE) | 100 | 76.3 | -23.7% |
| Medalist Diversifie… (MDRR) | 100 | 96.8 | -3.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SILA vs CHCT vs GMRE vs MDRR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SILA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.34, Low D/E 54.2%, current ratio 5488.22x
- Beta 0.34, yield 5.2%, current ratio 5488.22x
- 16.8% margin vs MDRR's -23.0%
- Beta 0.34 vs CHCT's 0.60, lower leverage
CHCT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 4.7%, EPS growth 133.7%, 3Y rev CAGR 7.5%
- Better valuation composite
GMRE is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.48, yield 63.5%
- 308.1% 10Y total return vs SILA's 55.9%
- 63.5% yield, 5-year raise streak, vs CHCT's 11.3%
MDRR is the clearest fit if your priority is growth.
- 6.8% FFO/revenue growth vs GMRE's -1.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.8% FFO/revenue growth vs GMRE's -1.8% | |
| Value | Better valuation composite | |
| Quality / Margins | 16.8% margin vs MDRR's -23.0% | |
| Stability / Safety | Beta 0.34 vs CHCT's 0.60, lower leverage | |
| Dividends | 63.5% yield, 5-year raise streak, vs CHCT's 11.3% | |
| Momentum (1Y) | +25.9% vs MDRR's +0.1% | |
| Efficiency (ROA) | 1.6% ROA vs MDRR's -2.9%, ROIC 2.5% vs 0.9% |
SILA vs CHCT vs GMRE vs MDRR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SILA vs CHCT vs GMRE vs MDRR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SILA leads in 3 of 6 categories
CHCT leads 0 • GMRE leads 0 • MDRR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SILA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SILA is the larger business by revenue, generating $198M annually — 19.0x MDRR's $10M. SILA is the more profitable business, keeping 16.8% of every revenue dollar as net income compared to MDRR's -23.0%. On growth, GMRE holds the edge at +18.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $198M | $122M | $148M | $10M |
| EBITDAEarnings before interest/tax | $145M | $82M | $95M | $4M |
| Net IncomeAfter-tax profit | $33M | $6M | $2M | -$2M |
| Free Cash FlowCash after capex | $111M | $60M | $19M | $12,992 |
| Gross MarginGross profit ÷ Revenue | +87.9% | +62.8% | +68.8% | — |
| Operating MarginEBIT ÷ Revenue | +34.5% | +31.3% | +24.9% | +5.3% |
| Net MarginNet income ÷ Revenue | +16.8% | +5.0% | +1.7% | -23.0% |
| FCF MarginFCF ÷ Revenue | +56.1% | +49.4% | +12.6% | +0.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.9% | +4.8% | +18.7% | +11.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.0% | +124.4% | -166.2% | -96.0% |
Valuation Metrics
Evenly matched — CHCT and GMRE and MDRR each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 51.0x trailing earnings, SILA trades at a 78% valuation discount to CHCT's 228.4x P/E. On an enterprise value basis, MDRR's 2.7x EV/EBITDA is more attractive than SILA's 16.8x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.7B | $505M | $94M | $12M |
| Enterprise ValueMkt cap + debt − cash | $2.4B | $1.0B | $741M | $11M |
| Trailing P/EPrice ÷ TTM EPS | 50.97x | 228.42x | 115.29x | -5.87x |
| Forward P/EPrice ÷ next-FY EPS est. | 47.05x | 37.62x | 595.67x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 16.76x | 16.27x | 8.35x | 2.70x |
| Price / SalesMarket cap ÷ Revenue | 8.55x | 4.17x | 0.68x | 1.19x |
| Price / BookPrice ÷ Book value/share | 1.28x | 1.11x | 0.17x | 0.58x |
| Price / FCFMarket cap ÷ FCF | 15.24x | 8.95x | — | 160.75x |
Profitability & Efficiency
SILA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SILA delivers a 2.4% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-10 for MDRR. MDRR carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CHCT's 1.25x. On the Piotroski fundamental quality scale (0–9), SILA scores 7/9 vs MDRR's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.4% | +1.4% | +0.5% | -9.5% |
| ROA (TTM)Return on assets | +1.6% | +0.6% | +0.2% | -2.9% |
| ROICReturn on invested capital | +2.5% | +1.6% | +2.0% | +0.9% |
| ROCEReturn on capital employed | +3.7% | +2.8% | +5.3% | +0.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.54x | 1.25x | 1.18x | 0.03x |
| Net DebtTotal debt minus cash | $689M | $533M | $647M | -$2M |
| Cash & Equiv.Liquid assets | $32M | $3M | $7M | $3M |
| Total DebtShort + long-term debt | $721M | $536M | $654M | $784,987 |
| Interest CoverageEBIT ÷ Interest expense | 2.01x | 1.15x | 1.14x | 0.21x |
Total Returns (Dividends Reinvested)
SILA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SILA five years ago would be worth $15,222 today (with dividends reinvested), compared to $5,441 for CHCT. Over the past 12 months, SILA leads with a +25.9% total return vs MDRR's +0.1%. The 3-year compound annual growth rate (CAGR) favors SILA at 13.7% vs CHCT's -13.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.8% | +11.2% | +6.9% | -9.0% |
| 1-Year ReturnPast 12 months | +25.9% | +14.5% | +0.1% | +0.1% |
| 3-Year ReturnCumulative with dividends | +47.0% | -36.1% | +5.6% | -2.3% |
| 5-Year ReturnCumulative with dividends | +52.2% | -45.6% | -21.4% | -36.1% |
| 10-Year ReturnCumulative with dividends | +55.9% | +83.9% | +308.1% | -80.2% |
| CAGR (3Y)Annualised 3-year return | +13.7% | -13.9% | +1.8% | -0.8% |
Risk & Volatility
Evenly matched — SILA and MDRR each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDRR is the less volatile stock with a -0.35 beta — it tends to amplify market swings less than CHCT's 0.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SILA currently trades 99.8% from its 52-week high vs MDRR's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.34x | 0.60x | 0.48x | -0.35x |
| 52-Week HighHighest price in past year | $30.63 | $18.22 | $39.93 | $14.52 |
| 52-Week LowLowest price in past year | $21.94 | $13.23 | $29.05 | $9.55 |
| % of 52W HighCurrent price vs 52-week peak | +99.8% | +97.0% | +89.5% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 87.8 | 56.9 | 52.7 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 741K | 228K | 130K | 1K |
Analyst Outlook
Evenly matched — CHCT and GMRE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SILA as "Buy", CHCT as "Hold", GMRE as "Buy". Consensus price targets imply 11.9% upside for GMRE (target: $40) vs -3.0% for SILA (target: $30). For income investors, GMRE offers the higher dividend yield at 63.51% vs MDRR's 4.29%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | — |
| Price TargetConsensus 12-month target | $29.67 | $18.50 | $40.00 | — |
| # AnalystsCovering analysts | 4 | 16 | 22 | — |
| Dividend YieldAnnual dividend ÷ price | +5.2% | +11.3% | +63.5% | +4.3% |
| Dividend StreakConsecutive years of raises | 3 | 11 | 5 | 0 |
| Dividend / ShareAnnual DPS | $1.60 | $2.00 | $22.70 | $0.48 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | +0.4% | 0.0% | +1.1% |
SILA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
SILA vs CHCT vs GMRE vs MDRR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SILA or CHCT or GMRE or MDRR a better buy right now?
For growth investors, Medalist Diversified REIT, Inc.
(MDRR) is the stronger pick with 6. 8% revenue growth year-over-year, versus -1. 8% for Global Medical REIT Inc. (GMRE). Sila Realty Trust, Inc. (SILA) offers the better valuation at 51. 0x trailing P/E (47. 0x forward), making it the more compelling value choice. Analysts rate Sila Realty Trust, Inc. (SILA) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SILA or CHCT or GMRE or MDRR?
On trailing P/E, Sila Realty Trust, Inc.
(SILA) is the cheapest at 51. 0x versus Community Healthcare Trust Incorporated at 228. 4x. On forward P/E, Community Healthcare Trust Incorporated is actually cheaper at 37. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SILA or CHCT or GMRE or MDRR?
Over the past 5 years, Sila Realty Trust, Inc.
(SILA) delivered a total return of +52. 2%, compared to -45. 6% for Community Healthcare Trust Incorporated (CHCT). Over 10 years, the gap is even starker: GMRE returned +308. 1% versus MDRR's -80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SILA or CHCT or GMRE or MDRR?
By beta (market sensitivity over 5 years), Medalist Diversified REIT, Inc.
(MDRR) is the lower-risk stock at -0. 35β versus Community Healthcare Trust Incorporated's 0. 60β — meaning CHCT is approximately -273% more volatile than MDRR relative to the S&P 500. On balance sheet safety, Medalist Diversified REIT, Inc. (MDRR) carries a lower debt/equity ratio of 3% versus 125% for Community Healthcare Trust Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — SILA or CHCT or GMRE or MDRR?
By revenue growth (latest reported year), Medalist Diversified REIT, Inc.
(MDRR) is pulling ahead at 6. 8% versus -1. 8% for Global Medical REIT Inc. (GMRE). On earnings-per-share growth, the picture is similar: Community Healthcare Trust Incorporated grew EPS 133. 7% year-over-year, compared to -79. 2% for Medalist Diversified REIT, Inc.. Over a 3-year CAGR, CHCT leads at 7. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SILA or CHCT or GMRE or MDRR?
Sila Realty Trust, Inc.
(SILA) is the more profitable company, earning 16. 8% net margin versus -23. 0% for Medalist Diversified REIT, Inc. — meaning it keeps 16. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SILA leads at 32. 9% versus 5. 3% for MDRR. At the gross margin level — before operating expenses — SILA leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SILA or CHCT or GMRE or MDRR more undervalued right now?
On forward earnings alone, Community Healthcare Trust Incorporated (CHCT) trades at 37.
6x forward P/E versus 595. 7x for Global Medical REIT Inc. — 558. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMRE: 11. 9% to $40. 00.
08Which pays a better dividend — SILA or CHCT or GMRE or MDRR?
All stocks in this comparison pay dividends.
Global Medical REIT Inc. (GMRE) offers the highest yield at 63. 5%, versus 4. 3% for Medalist Diversified REIT, Inc. (MDRR).
09Is SILA or CHCT or GMRE or MDRR better for a retirement portfolio?
For long-horizon retirement investors, Medalist Diversified REIT, Inc.
(MDRR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 35), 4. 3% yield). Both have compounded well over 10 years (MDRR: -80. 2%, CHCT: +83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SILA and CHCT and GMRE and MDRR?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.